BioLife Solutions Inc.

10 days ago · gurufocus.com

On October 23, 2026, BioLife Solutions Inc (BLFS) shares rose 3.5% to a current price of $38.61. The stock has shown a 52-week range between $17.86 and $39.76,

2 months ago · gurufocus.com

Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial be

3 months ago · zacks.com

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to break-even earnings per share a year ago.

3 months ago · prnewswire.com

Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026 BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc.  (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2026.

3 months ago · businesswire.com

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. Halper Sadeh encourages BioLife shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns w.

5 months ago · gurufocus.com

On May 28, 2026, BioLife Solutions Inc (BLFS) shares rose 3.1% to a current price of $25.25. This movement comes amid a 52-week range that sees a high of $29.62

6 months ago · seekingalpha.com

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

6 months ago · zacks.com

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.

6 months ago · zacks.com

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

6 months ago · prnewswire.com

BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.